Soleno CCO sells shares to cover RSU taxes

Soleno Therapeutics Chief Commercial Officer Meredith Manning reported open-market sales of a total of 7,522 shares of common stock of SOLENO THERAPEUTICS INC on March 27, 2026.

Rhea-AI Filing Summary

Soleno Therapeutics Chief Commercial Officer Meredith Manning reported open-market sales of a total of 7,522 shares of common stock of SOLENO THERAPEUTICS INC on March 27, 2026. According to the footnotes, these shares were sold to cover tax withholding obligations tied to vesting restricted stock units. After these transactions, Manning directly holds 64,507 shares of common stock.

Insider Trade Summary

Net Seller: 7,522 shares

Net Sell 3 txns

Insider Manning Meredith

Role Chief Commercial Officer

Sold 7,522 shs ($229K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,864	$30.037	$146K
Sale	Common Stock	2,100	$31.0384	$65K
Sale	Common Stock	558	$31.7187	$18K

Holdings After Transaction: Common Stock — 64,507 shares (Direct)

Footnotes (5)

1. F1. These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").
2. F2. This transaction was executed in multiple trades at prices ranging from $29.54 to $30.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. F3. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
4. F4. This transaction was executed in multiple trades at prices ranging from $30.545 to $31.41. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
5. F5. This transaction was executed in multiple trades at prices ranging from $31.64 to $31.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Key Figures

Shares sold: 7,522 shares Post-transaction holdings: 64,507 shares Sale price lot 1: $30.0370 per share +2 more

5 metrics

Shares sold 7,522 shares Open-market sales on March 27, 2026 to cover tax withholding

Post-transaction holdings 64,507 shares Common stock directly held after March 27, 2026 transactions

Sale price lot 1 $30.0370 per share Weighted average price for 4,864-share sale lot

Sale price lot 2 $31.0384 per share Weighted average price for 2,100-share sale lot

Sale price lot 3 $31.7187 per share Weighted average price for 558-share sale lot

Key Terms

restricted stock units ("RSUs"), tax withholding obligations, weighted average sale price, contingent right

4 terms

restricted stock units ("RSUs") financial

"in connection with the vesting of restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

tax withholding obligations financial

"sold to cover tax withholding obligations in connection with the vesting"

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

contingent right financial

"Each RSU represents a contingent right to receive one share of Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Soleno Therapeutics (SLNO) executive Meredith Manning report in this Form 4?

Meredith Manning reported selling 7,522 SLNO common shares. The transactions occurred on March 27, 2026 and were disclosed as open-market sales. Footnotes explain the sales were conducted to cover tax withholding obligations from vesting restricted stock units rather than discretionary share disposals.

How many Soleno Therapeutics (SLNO) shares does Meredith Manning hold after the reported sales?

After the transactions, Meredith Manning directly holds 64,507 SLNO shares. This post-transaction figure reflects her remaining ownership following the sale of 7,522 shares executed on March 27, 2026, as disclosed in the Form 4 filing’s ownership detail fields.

What was the purpose of Meredith Manning’s SLNO share sales reported in this Form 4?

The filing states the shares were sold to cover tax withholding obligations. A footnote clarifies the sales were linked to the vesting of restricted stock units, indicating the transactions were primarily to satisfy tax liabilities associated with equity compensation vesting.

At what prices were Meredith Manning’s Soleno Therapeutics (SLNO) shares sold?

The reported weighted average sale prices ranged around $30–$32 per share. Individual trade groups were executed at weighted averages of $30.0370, $31.0384, and $31.7187, with underlying trades occurring within specified price ranges noted in the footnotes.

What role does Meredith Manning hold at Soleno Therapeutics (SLNO)?

Meredith Manning serves as Chief Commercial Officer of Soleno Therapeutics. The Form 4 identifies her as an officer with this title, providing context that the reported transactions involve a senior executive directly holding and transacting in the company’s common stock.

Were Meredith Manning’s SLNO share sales executed in a single trade or multiple trades?

The sales were executed in multiple trades within defined price ranges. Footnotes explain separate transactions occurred in ranges such as $29.54–$30.52, $30.545–$31.41, and $31.64–$31.73, with the reported prices reflecting weighted average sale prices for each transaction group.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/31/2026 - 08:17 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Manning Meredith

(Last) (First) (Middle)

100 MARINE PARKWAY, SUITE 400

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOLENO THERAPEUTICS INC [ SLNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/27/2026		S(1)		4,864	D	$30.037(2)	67,165(3)	D
Common Stock	03/27/2026		S(1)		2,100	D	$31.0384(4)	65,065(3)	D
Common Stock	03/27/2026		S(1)		558	D	$31.7187(5)	64,507(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

2. This transaction was executed in multiple trades at prices ranging from $29.54 to $30.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

4. This transaction was executed in multiple trades at prices ranging from $30.545 to $31.41. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

5. This transaction was executed in multiple trades at prices ranging from $31.64 to $31.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

	/s/ Anish Bhatnagar, Attorney-in-Fact	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)